Home › SEC Filings › Current Report (8-K)
Current Report (8-K)
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| CBIO | 8-K | neutral | 3/10 | Crescent Biopharma provided a clinical pipeline update via an 8-K, announcing that the Phase 1/2 ASCEND trial of CR-001 | Oct 15, 2026 |
| AVXL | 8-K | neutral | 4/10 | Anavex received FDA clearance to proceed with its IND for blarcamesine in Fragile X syndrome, enabling a Phase 2a study | Oct 15, 2026 |
| OPK | 8-K | bullish | 7/10 | OPKO Health (OPK) has agreed to sell its BioReference clinical and anatomic pathology laboratory testing business, inclu | Oct 15, 2026 |
| EVFM | 8-K | neutral | 3/10 | Evofem Biosciences entered into a fifth amendment to its securities purchase agreement with Adjuvant, extending the matu | Oct 15, 2026 |
| ADTX | 8-K | bearish | 6/10 | Aditxt's wholly-owned subsidiary Ignite Proteomics mutually terminated its Business Combination Agreement with SPAC Copl | Oct 15, 2026 |
| MBIO | 8-K | bearish | 6/10 | Mustang Bio received Nasdaq notice that its stock failed to meet the $1.00 minimum bid price by the initial 180-day dead | Oct 15, 2026 |
| ABBV | 8-K | neutral | 2/10 | AbbVie expanded its Board of Directors from 12 to 13 members and appointed Dr. John M. Carethers as a Class II independe | Oct 15, 2026 |
| CRBP | 8-K | neutral | 5/10 | Corbus Pharmaceuticals filed an 8-K furnishing an updated corporate presentation. The presentation highlights Phase 1/2 | Oct 15, 2026 |
| BIAF | 8-K | neutral | 3/10 | bioAffinity Technologies filed an 8-K announcing a Learning Theater presentation at CHEST 2026 on October 21, 2026, high | Oct 15, 2026 |
| EDSA | 8-K | neutral | 4/10 | Edesa Biotech announced FDA clearance of its IND application for EB06, a monoclonal antibody targeting CXCL10, enabling | Oct 15, 2026 |
| RXRX | 8-K | mixed | 6/10 | Recursion Pharmaceuticals filed an 8-K announcing a $200M oversubscribed follow-on offering of 61.54M shares at $3.25/sh | Oct 15, 2026 |
| VVOS | 8-K | mixed | 6/10 | Vivos Therapeutics entered into a definitive agreement to acquire an 11% fully diluted equity stake in SOD Sciences and | Oct 15, 2026 |
| OCGN | 8-K | neutral | 5/10 | Ocugen posted an October 2026 corporate presentation on its website, providing a pipeline update across three gene thera | Oct 15, 2026 |
| JSPR | 8-K | neutral | 3/10 | Jasper Therapeutics completed enrollment of the IgA nephropathy (IgAN) cohort in its Phase 2 basket study of vensobafusp | Oct 15, 2026 |
| AQST | 8-K | bullish | 7/10 | Aquestive Therapeutics announced that the FDA has accepted its resubmission of the New Drug Application (NDA) for Anaphy | Oct 15, 2026 |
| KRYS | 8-K | bullish | 6/10 | Krystal Biotech announced positive proof-of-concept clinical data for KB113, an intratumoral immunotherapy for basal cel | Oct 15, 2026 |
| TNXP | 8-K | bullish | 5/10 | Tonix Pharmaceuticals disclosed preliminary Q3 2026 TONMYA net revenue of $14M-$15M, up 27-36% sequentially from Q2's $1 | Oct 15, 2026 |
| IDXG | 8-K | bullish | 5/10 | Interpace Biosciences announced preliminary Q3 2026 revenue of $10.1M-$10.4M, representing ~15-18% YoY growth and ~11-14 | Oct 15, 2026 |
| OCGN | 8-K | mixed | 5/10 | Ocugen entered into an exclusive license agreement with Roots Pharmaceutical for OCU400, a modifier gene therapy for ret | Oct 14, 2026 |
| VSTM | 8-K | bearish | 6/10 | Verastem priced a public offering of 30,937,500 shares of common stock at $8.00/share and pre-funded warrants to purchas | Oct 14, 2026 |
| IBRX | 8-K | bullish | 7/10 | ImmunityBio announced FDA approval expanding ANKTIVA's indication to include BCG-unresponsive NMIBC patients with papill | Oct 14, 2026 |
| MTEX | 8-K | bullish | 5/10 | Mannatech filed an 8-K reporting it has entered into a share purchase agreement to acquire 100% direct ownership of Mann | Oct 14, 2026 |
| RZLT | 8-K | neutral | 5/10 | Rezolute announced completion of enrollment in its Phase 3 upLIFT study of ersodetug for tumor hyperinsulinism, with top | Oct 14, 2026 |
| ELVN | 8-K | neutral | 3/10 | Enliven Therapeutics appointed Kristine Ball to its Board of Directors, effective October 14, 2026, and disclosed plans | Oct 14, 2026 |
| SILO | 8-K | neutral | 3/10 | Silo Pharma acquired software and IP assets marketed as 'Reputation Endpoints' from Larry King in exchange for 150,000 r | Oct 14, 2026 |
| LSTA | 8-K | neutral | 2/10 | Lisata Therapeutics appointed Jeffrey Farrow to its Board of Directors, filling a newly created seat (expanding the boar | Oct 14, 2026 |
| CRVO | 8-K | neutral | 2/10 | CervoMed Inc. filed an 8-K under Item 7.01 to disclose that an investor presentation containing information about its bu | Oct 14, 2026 |
| LGVN | 8-K | neutral | 3/10 | Longeveron Inc. disclosed that Dr. Nataliya Agafonova stepped down as Chief Medical Officer, effective October 14, 2026. | Oct 14, 2026 |
| ONCY | 8-K | neutral | 3/10 | Oncolytics Biotech provided an update on its GOBLET Phase 1/2 study, announcing it expects to receive the final grant pa | Oct 14, 2026 |
| RARE | 8-K | bullish | 6/10 | Ultragenyx entered into an asset purchase agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $ | Oct 14, 2026 |